Live Webinar Recap: Big Ideas 2026

ARK Invest identifies five major innovation platforms converging to create what it calls «the great acceleration»: artificial intelligence as the central accelerant, multiomics (genomics and biological data), public blockchains including stablecoins and Bitcoin, robotics including humanoid and specialized robots, and reusable rockets. Each platform is hitting a critical stage of inflection simultaneously, leading to an unprecedented investment cycle. The scale of capital deployment rivals only the railroad boom of the 1870s as a percentage of GDP.

This convergence is already producing measurable macroeconomic impact. Data centers are driving marginal GDP activity, and the accelerating investment in AI agents is transforming the business landscape. Arc forecasts that this infrastructure buildout will generate positive returns and sustain compounded real global GDP growth exceeding 7% through the end of the decade. Historically, such inflections in growth rates occur only during major technology transitions—the kind that redefine economic equilibria.

The equity market implications are stark. Arc projects that more than 60% of total global equity market capitalization will accrue to disruptive innovation platforms by 2030. Investors holding traditional portfolios risk being left behind as innovation companies capture exponentially more value. The firm draws a historical parallel: in the late 1870s, 75% of US equity market cap was attributed to railroads during a similar infrastructure buildout. The message is clear—exposure to innovation is no longer optional.

The convergence of AI and biology is creating what Arc calls a virtuous flywheel: better data feeds better models, which produce better diagnostics and therapeutics, which generate richer data. The team organizes this cycle around four pillars—multiomics tools, molecular diagnostics, AI-developed drugs, and curative therapies—each reinforcing the others. The Human Genome Project took 13 years and cost nearly $3 billion to sequence the first genome. Today, a whole human genome can be sequenced for $100. By 2030, Arc forecasts that cost will fall to $10.

This cost curve is fundamentally changing the paradigm for who gets tested, how often, and the volume of data generated. Arc projects the volume of genomic tests will double by 2030, and the total tokens generated will already rival the tokens used to train frontier large language models—then scale another 10x by decade's end. The data explosion is staggering: the human body contains 35 to 40 trillion cells, and single-cell sequencing is now possible. This is creating one of the largest data generation engines on the planet, powering a transformation across the entire healthcare spectrum.

The sticker shock of gene therapies can be misleading. CRISPR Therapeutics' Casgevy, a gene editing treatment for sickle cell disease and beta-thalassemia, is priced at just over $2 million—yet 90% of US patients have reimbursement access. The reason: insurers compare the one-time cure price against the lifetime cost of chronic treatments and hospitalizations, which can reach $10 to $20 million. The cure saves the healthcare system money while delivering better patient outcomes, justifying the upfront price. Arc's modeling suggests cures can be up to 20 times more valuable than traditional chronic therapies because they frontload cash, capture more patent-protected revenue, and avoid competitive overlap.

A case study illustrates the economics. Hereditary angioedema (HAE) causes painful, sometimes life-threatening swelling episodes, requiring patients to remain on chronic treatment costing $10–$20 million over their lifetime. Intellia Therapeutics is developing a gene editing treatment with promising clinical data that Arc estimates could be priced at $3 million (though the value-based price could be 3–4x higher). Applying this to all 7,000 US HAE patients represents a $52 billion cost savings to the healthcare system—even with the high upfront price. Patients eliminate the burden of lifelong symptom management.

The scaling story is equally compelling. Gene editing is transitioning from rare diseases to common conditions, including cardiovascular disease—the world's leading killer. Moving to in vivo editing (edits within the body) enables this shift. For cardiovascular applications, Arc models a value-based price of $165,000—dramatically lower than rare disease therapies—yet the total addressable market is $2.8 trillion for just the highest-risk US patients. Capturing one-twelfth of that TAM would match the cumulative sales of Lipitor, the best-selling drug of all time, over 20 years.

Autonomous vehicles represent the first large-scale implementation of embodied AI that consumers will experience, and it's already happening today. Cars with no one behind the wheel or in the passenger seat are picking up passengers in multiple cities. The underlying cost of the vehicle is critical, especially in the early days of commercialization when fleets are small and partners need convincing. Tesla's Model Y already holds a cost advantage: on an incremental cost-per-mile basis, it's over 30% cheaper than Waymo's fifth-generation vehicle. Arc expects that advantage to widen to 50% with the Cybercab versus Waymo's sixth-generation car.

Cost per mile is the metric that will drive consumer demand and market expansion. Arc believes the lowest possible price a robo taxi platform could charge at scale is around 25 cents per mile. To put that in perspective: it's less than one-tenth the cost of human-driven ride hail in Western markets, less than half the cost of driving your personal car, and cheaper than ride hail in China (which is already very inexpensive at around 50 cents per mile). This dramatic cost reduction will make low-cost point-to-point travel available to vastly more people than those who currently use ride hail services, while also making roads significantly safer.

The market potential is staggering. Arc projects robo taxis could generate $34 trillion in enterprise value opportunity by the end of the decade, accruing primarily to autonomous technology providers and platform operators—the companies developing the self-driving technology in-house and offering ride-hailing services. Total revenue TAM could reach $10 trillion or above, with revenue and earnings around $2 trillion by 2030. The platform operators capture the lion's share of economics because they enable the low prices per mile that expand the market. Electric vehicles are crucial to attractive cost-per-mile economics, which is why Arc expects the future of robo taxis to be electric.